dbo:abstract
|
- Maribavir (Markenname Livtencity) ist ein antiviraler Wirkstoff, der zur Behandlung des Zytomegalievirus (CMV) nach einer Transplantation eingesetzt wird. Maribavir wurde im November 2021 in den Vereinigten Staaten für die medizinische Verwendung zugelassen. (de)
- Maribavir, sold under the brand name Livtencity, is an antiviral medication that is used to treat post-transplant cytomegalovirus (CMV). The most common side effects include taste disturbance, nausea, diarrhea, vomiting and fatigue. Maribavir is a cytomegalovirus pUL97 kinase inhibitor that works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication. Maribavir was approved for medical use in the United States in November 2021, and in the European Union in November 2022. (en)
|
dbo:alternativeName
| |
dbo:casNumber
| |
dbo:chEMBL
| |
dbo:drugbank
| |
dbo:fdaUniiCode
| |
dbo:kegg
| |
dbo:pubchem
| |
dbo:thumbnail
| |
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 17837 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:atcPrefix
| |
dbp:atcSuffix
| |
dbp:c
| |
dbp:casNumber
| |
dbp:chembl
| |
dbp:chemspiderid
| |
dbp:cl
| |
dbp:dailymedid
| |
dbp:drugbank
| |
dbp:h
| |
dbp:iupacName
| |
dbp:kegg
| |
dbp:legalCa
| |
dbp:legalEu
| |
dbp:legalUs
| |
dbp:n
| |
dbp:niaidChemdb
| |
dbp:o
| |
dbp:pubchem
| |
dbp:routesOfAdministration
| |
dbp:smiles
| |
dbp:stdinchi
| |
dbp:stdinchikey
|
- KJFBVJALEQWJBS-XUXIUFHCSA-N (en)
|
dbp:synonyms
| |
dbp:tradename
| |
dbp:unii
| |
dbp:verifiedfields
| |
dbp:verifiedrevid
| |
dbp:watchedfields
| |
dbp:wikiPageUsesTemplate
| |
dct:subject
| |
gold:hypernym
| |
rdf:type
| |
rdfs:comment
|
- Maribavir (Markenname Livtencity) ist ein antiviraler Wirkstoff, der zur Behandlung des Zytomegalievirus (CMV) nach einer Transplantation eingesetzt wird. Maribavir wurde im November 2021 in den Vereinigten Staaten für die medizinische Verwendung zugelassen. (de)
- Maribavir, sold under the brand name Livtencity, is an antiviral medication that is used to treat post-transplant cytomegalovirus (CMV). The most common side effects include taste disturbance, nausea, diarrhea, vomiting and fatigue. Maribavir is a cytomegalovirus pUL97 kinase inhibitor that works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication. Maribavir was approved for medical use in the United States in November 2021, and in the European Union in November 2022. (en)
|
rdfs:label
|
- Maribavir (de)
- Maribavir (en)
|
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |